title: Incremental prognostic value of RNA ejection fraction measurements during pharmacologic stress testing: a comparison with clinical and perfusion variables.
abstract: This investigation examined the prognostic power of first-pass radionuclide angiocardiography (RNA) ejection fraction compared with clinical information and myocardial perfusion imaging in patients undergoing pharmacologic stress testing. The value of RNA and myocardial perfusion imaging in predicting death or nonfatal myocardial infarction (MI) is well established. However, limited information exists on the usefulness of combined myocardial perfusion imaging and RNA to predict prognosis, especially in patients undergoing pharmacologic stress testing.
  
  
  METHODS
  We identified 240 patients who underwent pharmacologic stress testing with myocardial perfusion imaging and combined RNA. The patients were followed for a mean of 1.4 y. Cox proportional hazards models were used to assess the value in predicting death and MI. Multivariable models were generated to assess the independent incremental predictive value of clinical and nuclear imaging variables. Kaplan-Meier survival and event-free survival estimates were examined in patients with low (< or = 45%) versus high (>45%) ejection fractions.
  
  
  RESULTS
  Clinical information, myocardial perfusion imaging, and RNA ejection fraction were significant predictors of the death/MI composite outcome (chi(2) = 7.4, 14.0, and 21.8, respectively). The addition of myocardial perfusion imaging to the clinical information provided incremental prognostic information (chi(2) = 15.2). The addition of RNA ejection fraction provided further predictive information (chi(2) = 22.5). However, when RNA ejection fraction was first added to the clinical information, myocardial perfusion imaging had no incremental prognostic value.
  
  
  CONCLUSIONS
  For hard cardiac events, RNA ejection fraction provides prognostic information besides that provided by clinical and myocardial perfusion imaging. In patients who cannot exercise and are undergoing noninvasive evaluation with pharmacologic stress testing and myocardial perfusion imaging, ejection fraction should be measured simultaneously for risk assessment optimization.
authors.affiliation: Division of Cardiology, Department of Internal Medicine, Duke University Medical Center and Health Systems, Durham, North Carolina 27710, USA.
authors.forename: S T
authors.initials: ST
authors.lastname: Mast
authors.forename: L K
authors.initials: LK
authors.lastname: Shaw
authors.forename: G C
authors.initials: GC
authors.lastname: Ravizzini
authors.forename: M
authors.initials: M
authors.lastname: Chambless
authors.forename: P
authors.initials: P
authors.lastname: Joski
authors.forename: R E
authors.initials: RE
authors.lastname: Coleman
authors.forename: S
authors.initials: S
authors.lastname: Borges-Neto
mesh_terms: D000241:Adenosine; D000368:Aged; D002316:Cardiotonic Agents; D002395:Catecholamines; D003326:Coronary Circulation; D003327:Coronary Disease / Q000000981:diagnostic imaging*; D004176:Dipyridamole; D004280:Dobutamine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D019275:Radiopharmaceuticals; D013318:Stroke Volume; D016019:Survival Analysis; D017256:Technetium Tc 99m Sestamibi; D014665:Vasodilator Agents; D015646:Ventriculography, First-Pass
chemical_list: D002316:Cardiotonic Agents; D002395:Catecholamines; D019275:Radiopharmaceuticals; D014665:Vasodilator Agents; D004280:Dobutamine; D004176:Dipyridamole; D017256:Technetium Tc 99m Sestamibi; C076559:arbutamine; D000241:Adenosine